Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial.

UNLABELLED TRIAL DESIGN AND METHODS: Between December 2009 and July 2011, four cystic fibrosis (CF) centers in Italy participated in a randomized, double-blind, controlled clinical trial to test whether 7% hypertonic saline (HS) administered together with 0.1% hyaluronic acid (HA) was better tolerated by patients who previously did not tolerate HS well on its own. Participants were CF patients at least 8 years old, in clinically stable conditions, with forced expiratory volume in 1 sec (FEV1) at least 50% predicted. Forty patients were recruited and randomized to receive either HS or HS plus HA (5 mL to be inhaled over 15 min, twice daily for 28 days). Primary endpoints were cough, throat irritation, salty taste, and overall acceptability, as assessed by each patient on a semiquantitative scale on a diary card. Secondary endpoint was FEV1 change at the end of treatment. Patients were randomized into randomly permuted blocks. The first and last doses were administered in hospital. In between, patients were treated at home. Patients, all caregivers, and the statistician who conducted the analysis (different from the one who generated the random list) were blinded to group assignment. RESULTS Severity of cough, throat irritation, and saltiness were more severe in patients treated with HS alone, both after the first inhalation and over the entire treatment period. Overall pleasantness was rated higher by patients treated with the combination product. All differences were highly significant. There were no changes in FEV1 between the first and last administrations. Five patients did not complete the study. Four patients (two from each group) withdrew because of cough or throat irritation. One more patient from the HS group withdrew because of a respiratory exacerbation at week 3. CONCLUSIONS HS is currently a cornerstone in the treatment of CF patients. The addition of HA to HS reduces the prevalence and severity of cough, throat irritation, and saltiness and may improve compliance in patients who previously did not tolerate HS well on its own. Longer-term studies could further assess the benefit of chronic treatment.

[1]  L. S. Cortina,et al.  [Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis]. , 2012, Medicina clinica.

[2]  J. Zahm,et al.  The effect of hyaluronan on airway mucus transport and airway epithelial barrier integrity: potential application to the cytoprotection of airway tissue. , 2011, Matrix biology : journal of the International Society for Matrix Biology.

[3]  M. Kraft,et al.  Role of hyaluronan and hyaluronan-binding proteins in human asthma. , 2011, The Journal of allergy and clinical immunology.

[4]  Frances E. Lennon,et al.  High-molecular-weight hyaluronan is a novel inhibitor of pulmonary vascular leakiness. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[5]  V. Raia,et al.  Hyaluronic acid improves “pleasantness” and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis , 2010, Advances in therapy.

[6]  E. Fedrigo,et al.  Hyaluronic acid in the prevention of bronchial obstruction induced by hypertonic saline , 2010 .

[7]  R. Boucher,et al.  Osmolytes and ion transport modulators: new strategies for airway surface rehydration. , 2010, Current opinion in pharmacology.

[8]  S. Donaldson,et al.  Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis , 2008, Pediatric pulmonology.

[9]  R. Boucher.  Cystic fibrosis: a disease of vulnerability to airway surface dehydration. , 2007, Trends in molecular medicine.

[10]  R. Boucher,et al.  The epithelium as a target for therapy in cystic fibrosis. , 2007, Current opinion in pharmacology.

[11]  R. Tarran,et al.  Rationale for Hypertonic Saline Therapy for Cystic Fibrosis Lung Disease , 2007, Seminars in respiratory and critical care medicine.

[12]  F. Ratjen,et al.  Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis , 2007, Pediatric pulmonology.

[13]  R. Boucher.  Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. , 2007, Annual review of medicine.

[14]  F. Ratjen.  Restoring airway surface liquid in cystic fibrosis. , 2006, The New England journal of medicine.

[15]  Mark R Elkins,et al.  A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. , 2006, The New England journal of medicine.

[16]  M. Knowles,et al.  Mucus clearance and lung function in cystic fibrosis with hypertonic saline. , 2006, The New England journal of medicine.

[17]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[18]  R. Niven,et al.  Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. , 2005, Respiratory medicine.

[19]  Richard C Boucher,et al.  Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice , 2004, Nature Medicine.

[20]  G. Turino,et al.  Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema? , 2004, Chest.

[21]  W. Abraham,et al.  Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep. , 2003, Pulmonary pharmacology & therapeutics.

[22]  G. Turino,et al.  Hyaluronan in respiratory injury and repair. , 2003, American journal of respiratory and critical care medicine.

[23]  P. Noble.  Hyaluronan and its catabolic products in tissue injury and repair. , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[24]  R. Savani,et al.  Hyaluronan serves a novel role in airway mucosal host defense , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  S. Randell,et al.  Evidence for Periciliary Liquid Layer Depletion, Not Abnormal Ion Composition, in the Pathogenesis of Cystic Fibrosis Airways Disease , 1998, Cell.

[26]  T. Ando,et al.  Suppressive Effects of Hyaluronic Acid on Elastase Release from Rat Peritoneal Leucocytes , 1993, The Journal of pharmacy and pharmacology.